ArticleFrontiers in oncology2025
Construction of a novel cuproptosis-related gene signature for predicting microenvironment, prognosis and therapeutic response in cervical cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer is a common malignant tumor in females, and its carcinogenesis needs further elucidation. Cuproptosis is a novel mode of cell death and its role in cervical cancer is largely unknown. Methods: The data of 334 cases of cervical cancer patients were extracted from public databases, including TCGA, GEO, GSCA and Msigdb databases. The R package, Kaplan-Meier and Cox regression analysis were used to construct the prediction model. To confirm the validation of the model, FOXJ1 was over-expressed in HeLa and SiHa cells. CCK-8, EdU, colony formation and Transwell assays were used to test the proliferation, invasion and migration abilities. Western blotting was utilized to examine the changes of protein levels. Results: We constructed a six-gene signature based on cuproptosis-related genes (CRGs) using consensus clustering analysis which further classified the patients into Cluster A and Cluster B. Kaplan-Meier survival analysis revealed that the prognosis of patients with cervical cancer in Cluster B was significantly better than in Cluster A (p=0.027). By analyzing the differentially expressed genes (DEGs), we optimized the subclassification as high and low DEG score types, and revealed their differences in prognosis, copy number variation and single nucleotide variation. The scoring model showed effectiveness in distinguishing prognosis, tumor staging, immune microenvironment, immunotherapy and chemotherapy sensitivity. Moreover, the overexpression of FOXJ1 (one of the DEGs) significantly decreased the proliferation, invasion, migration and Epithelial-Mesenchymal Transition (EMT) process in cervical cancer cells. FOXJ1 promoted cuproptosis in cervical cancer cells, thereby inhibiting their proliferation, migration, and invasion capabilities. Conclusion: Our study sheds light on the role of cuproptosis in carcinogenesis and is expected to facilitate the development of personalized treatment for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.